Novonesis to acquire remaining share of MicroBioGen to strengthen yeast capabilities

Novonesis 将收购 MicroBioGen 剩余股份以增强酵母技术能力

COPENHAGEN, Denmark, August 10 –

丹麦哥本哈根，8月10日 –

Novonesis has signed an agreement with the intent to acquire MicroBioGen, an Australian biotechnology company with leading scientific expertise in yeast strains for industrial applications, particularly in bioethanol.

Novonesis已签署一项意向协议，拟收购澳大利亚生物技术公司MicroBioGen，该公司在用于工业应用（尤其是生物乙醇）的酵母菌株方面拥有领先的科学专长。

The acquisition builds on Novonesis’ 2013 investment in MicroBioGen and its current 23% stake, further strengthening a decade-long collaboration in advanced yeast solutions for bioethanol production.

此次收购建立在Novonesis于2013年对MicroBioGen的投资及其目前持有的23%股权基础之上，进一步强化了双方在生物乙醇生产先进酵母解决方案领域长达十年的合作关系。

Ester Baiget, CEO: 'This acquisition marks an additional step in our 2030 strategy. It strengthens our yeast capabilities, strengthens our R&D capabilities, and reflects our disciplined investment focus to drive growth.'

Ester Baiget，首席执行官：“此次收购是我们2030战略的又一重要步骤。它增强了我们的酵母业务能力和研发实力，也体现了我们以纪律性投资推动增长的专注。”

Building on deep scientific expertise

依托深厚的科学专业知识

As a pure-play biology company, Novonesis combines deep scientific expertise in microbiology and industrial fermentation with approximately 10% of annual sales investment in innovation. The acquisition of MicroBioGen builds on this foundation, strengthening core expertise in biological solutions.

作为一家专注生物领域的公司，Novonesis 将深厚的微生物学与工业发酵科学专业知识与每年约10%的销售收入创新投入相结合。对 MicroBioGen 的收购在此基础上进一步巩固了其在生物解决方案方面的核心专业能力。

'We see MicroBioGen as a perfect match building on more than a decade of close collaboration, and we look forward to integrating their technology into Novonesis. With the acquisition, we will continue to strengthen our capabilities and develop the biosolutions our customers need,” said Claus Crone Fuglsang, Chief Scientific Officer, Novonesis..

“我们认为，基于十多年的密切合作，MicroBioGen 是完美的契合对象，我们期待将其技术整合到 Novonesis 中。通过此次收购，我们将继续增强我们的能力，并开发客户所需的生物解决方案。”Novonesis 首席科学官 Claus Crone Fuglsang 表示。

As part of the agreement, Novonesis will continue to support MicroBioGen's existing partners and ensure continuity in its collaborations.

根据协议，Novonesis 将继续支持 MicroBioGen 的现有合作伙伴，并确保其合作的连续性。

Geoffrey Bell, CEO and Co-founder of MicroBioGen, said: 'Joining Novonesis is a strong fit for MicroBioGen and its employees. After more than a decade of close collaboration, we could not think of a better home for the company.'

MicroBioGen 首席执行官兼联合创始人杰弗里·贝尔表示：“加入 Novonesis 对 MicroBioGen 及其员工而言是一个极佳的选择。经过十多年的紧密合作，我们认为该公司没有比这更好的归宿了。”

The terms of the transaction will not be disclosed, and completion of the transaction is subject to customary regulatory approvals, including by the ACCC (Australia's national competition, consumer, fair trading and product safety regulator).

交易条款将不予披露，且交易的完成须取决于惯常的监管审批，包括获得澳大利亚竞争与消费者委员会（ACCC，澳大利亚的国家竞争、消费者、公平交易及产品安全监管机构）的批准。

About MicroBioGen

关于 MicroBioGen

MicroBioGen is an Australian based biotechnology company with global success in improving the industrial capabilities of yeast. With a platform technology and library of elite yeast genetics, developed over 20 years, MicroBioGen delivers ‘Yeast Innovation as a Service’ to industry leaders globally. Demonstrated through MicroBioGen’s bioethanol partnership with Novonesis and co-developing the Innova® yeast series which delivers exceptional industrial performance, MicroBioGen is a leading collaborator for yeast biotechnology, with opportunities in existing and emerging industries, ranging from optimising yeast for baking, sustainable feed and energy to food applications. .

MicroBioGen 是一家总部位于澳大利亚的生物技术公司，在提升酵母工业性能方面取得了全球性的成功。凭借历经20余年开发的平台技术和精英酵母基因库，MicroBioGen 向全球行业领袖提供“酵母创新即服务”（Yeast Innovation as a Service）。通过与 Novonesis 建立生物乙醇合作伙伴关系，并共同开发出具有卓越工业性能的 Innova® 酵母系列，MicroBioGen 证明了其在酵母生物技术领域的领先地位。作为一家领先的酵母生物技术合作方，MicroBioGen 在现有和新兴行业中拥有广泛机遇，业务涵盖从优化烘焙用酵母、可持续饲料和能源到食品应用等多个领域。

For more information, visit

欲了解更多信息，请访问

www.microbiogen.com

www.microbiogen.com

Get in touch

联系我们

Media relations

媒体关系

Benjamin Hjorth

本杰明·约尔特

Senior Press Manager

高级新闻经理

media-relations@novonesis.com

media-relations@novonesis.com

+45 30 77 13 12

+45 30 77 13 12

Attachment

附件

Press release_Novonesis to acquire remaining share of MicroBioGen_FINAL

新闻稿_Novonesis将收购MicroBioGen剩余股份_最终版